Bruce Booth
Principal, Atlas Ventures

Bruce Booth joined Atlas Venture in 2005 as a Principal on the Life Sciences team. Prior to Atlas Venture, Bruce was a Principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm. He focused on the firm?s private equity activities, ranging from early stage venture capital through late stage buyouts. Prior to joining Caxton Health, he was an Associate Principal at McKinsey & Company, a global strategic management consulting firm, where he focused on R&D productivity, corporate strategy, and business development issues for several major biopharmaceutical companies. While at McKinsey, he also co-led the Firm?s international scholars recruiting efforts. Bruce works closely with Atlas Venture portfolio companies ARCA Discovery, Archemix, Dynogen and NxStage Medical. As a British Marshall Scholar, Bruce earned a Doctorate in Molecular Immunology from the Oxford University?s Nuffield Department of Medicine and the Weatherall Institute of Molecular Medicine. His research focused on viral and tumor immune surveillance, and how the immune system responds to intracellular pathogenesis. During his graduate studies at Oxford, he also received the Overseas Research Fellowship and served as junior dean of Trinity College. Prior to graduate studies, he worked on President Clinton?s Domestic Policy Council in the National Office of AIDS Policy. He received a Bachelor of Science degree with highest honors in Biochemistry from the Pennsylvania State University, where he was an Evan Pugh Scholar. He currently serves on the New York Academy of Medicine Board of Trustees, and is an active member of the Council on Foreign Relations. Bruce has also authored numerous scientific papers and reviews, including several in Nature Reviews Drug Discovery.